突发性聋患者早期针刺介入的临床观察及基于SIRT1表达探讨针刺对于强化突发性聋激素治疗的机制研究

注册号:

Registration number:

ChiCTR2400084809 

最近更新日期:

Date of Last Refreshed on:

2024-05-24 16:32:09 

注册时间:

Date of Registration:

2024-05-24 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

突发性聋患者早期针刺介入的临床观察及基于SIRT1表达探讨针刺对于强化突发性聋激素治疗的机制研究

Public title:

Clinical observation of early acupuncture intervention in patients with sudden hearing loss and the mechanism of acupuncture for intensive hormone therapy for sudden hearing loss based on the expression of SIRT1

注册题目简写:

English Acronym:

研究课题的正式科学名称:

突发性聋患者早期针刺介入的临床观察及基于SIRT1表达探讨针刺对于强化突发性聋激素治疗的机制研究

Scientific title:

Clinical observation of early acupuncture intervention in patients with sudden hearing loss and the mechanism of acupuncture for intensive hormone therapy for sudden hearing loss based on the expression of SIRT1

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

辛忠海 

研究负责人:

辛忠海 

Applicant:

Xin Zhonghai 

Study leader:

Xin Zhonghai 

申请注册联系人电话:

Applicant telephone:

+86 18513081792

研究负责人电话:

Study leader's
telephone:

+86 10 84739019

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xzh_d716@163.com

研究负责人电子邮件:

Study leader's E-mail:

xzh_d716@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区中环南路6号

研究负责人通讯地址:

北京市朝阳区中环南路6号

Applicant address:

6 Zhonghuan South Road, Chaoyang District, Beijing

Study leader's address:

6 Zhonghuan South Road, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院望京医院

Applicant's institution:

Wangjing Hospital of China Academy of Chinese Medical Sciences

研究负责人所在单位:

中国中医科学院望京医院

Affiliation of the Leader:

Wangjing Hospital of China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

WJEC-KT-2022-028-P002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院望京医院医学伦理委员会

Name of the ethic committee:

Medical Ethic Committee of China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2022-07-21 00:00:00

伦理委员会联系人:

王浩

Contact Name of the ethic committee:

Hao Wang

伦理委员会联系地址:

北京市朝阳区中环南路6号

Contact Address of the ethic committee:

6 Zhonghuan South Road, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 84739681

伦理委员会联系人邮箱:

Contact email of the ethic committee:

peterxfx@126.com

研究实施负责(组长)单位:

中国中医科学院望京医院

Primary sponsor:

Wangjing Hospital of China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区中环南路6号

Primary sponsor's address:

6 Zhonghuan South Road, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院

具体地址:

北京市朝阳区中环南路6号

Institution
hospital:

Wangjing Hospital of China Academy of Chinese Medical Sciences

Address:

6 Zhonghuan South Road, Chaoyang District, Beijing

经费或物资来源:

中国中医科学院科技创新工程

Source(s) of funding:

Science and technology Innovation Project of China Academy of Chinese Medical Sciences

研究疾病:

突发性聋  

Target disease:

Sudden Deafness

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

证明针刺早期介入突发性聋患者可以提高突发性聋的鼓室激素治疗效果。 证明针刺可以加强激素的治疗效果,帮助突聋大鼠模型听力恢复。 证明SIRT1的表达水平会增强抗氧化应激能力,提高激素敏感性,保护耳蜗毛细胞,并探索其作用机制。  

Objectives of Study:

It is proved that early intervention of acupuncture in patients with sudden deafness can improve the effect of tympanic hormone therapy for sudden deafness. It was proved that acupuncture can enhance the therapeutic effect of hormones and help hearing recovery in rat models with sudden deafness. It was demonstrated that SIRT1 expression levels enhance antioxidant stress, improve hormone sensitivity, protect cochlear hair cells, and explore their mechanism of action.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有激素禁忌症。 (2)妊娠期、糖尿病、高血压患者。 (3)患有梅尼埃病、中耳病变、大前庭水管综合征、听神经瘤等病变。 (4)患有癫痫、精神分裂症等神经、精神疾病。 (5)经研究者判断不能完成试验者。 (6)全频率听力损失,低于70db;

Exclusion criteria:

1. Hormone contraindications. (2) Pregnancy, diabetes, hypertension patients. (3) Patients with Meniere's disease, middle ear disease, large vestibular duct syndrome, acoustic neuroma and other diseases. (4) suffering from epilepsy, schizophrenia and other neurological and mental diseases. (5) Those judged by the researcher to be unable to complete the experiment. (6) Full frequency hearing loss, less than 70db;

研究实施时间:

Study execute time:

From 2021-10-01 00:00:00 To 2024-11-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-07-21 00:00:00 To 2023-07-21 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

80

Group:

Control group

Sample size:

干预措施:

鼓室注射地塞米松+口服营养神经(甲钴胺)及改善循环(银杏叶提取物)药物

干预措施代码:

Intervention:

Tympanic injection of dexamethasone + oral neurotrophic (mecobalamine) and circulatory improvement (Ginkgo biloba extract) drugs

Intervention code:

组别:

试验组

样本量:

80

Group:

Experimental group

Sample size:

干预措施:

鼓室注射地塞米松+口服营养神经(甲钴胺)及改善循环(银杏叶提取物)药物+针刺

干预措施代码:

Intervention:

Tympanic injection of dexamethasone + oral neurotrophic (mecobalamine) and circulatory improvement (Ginkgo biloba extract) drugs + acupuncture

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院 

单位级别:

三级甲等 

Institution
hospital:

Wangjing Hospital of China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

纯音测听检查

指标类型:

主要指标

Outcome:

Pure tone audiometry

Type:

Primary indicator

测量时间点:

每次治疗前及末次治疗后各一次

测量方法:

纯音测听

Measure time point of outcome:

Once before each treatment and once after the last treatment

Measure method:

pure tone test

指标中文名:

耳鸣评分

指标类型:

次要指标

Outcome:

Tinnitus score

Type:

Secondary indicator

测量时间点:

每次测量听力时

测量方法:

耳鸣评估量表

Measure time point of outcome:

Every time you measure your hearing

Measure method:

Tinnitus assessment Scale

指标中文名:

基线资料

指标类型:

主要指标

Outcome:

Baseline data

Type:

Primary indicator

测量时间点:

治疗前

测量方法:

纯音测听

Measure time point of outcome:

prior treatment

Measure method:

pure tone test

指标中文名:

疾病痊愈时间/率

指标类型:

主要指标

Outcome:

Disease recovery time/rate

Type:

Primary indicator

测量时间点:

每次治疗前、全部治疗结束时各评价1次。

测量方法:

纯音测听

Measure time point of outcome:

Evaluation was performed once before each treatment and once at the end of all treatment.

Measure method:

pure tone test

指标中文名:

受损频率听力改善情况

指标类型:

次要指标

Outcome:

Hearing improvement at impaired frequencies

Type:

Secondary indicator

测量时间点:

治疗结束后

测量方法:

纯音测听

Measure time point of outcome:

After treatment

Measure method:

pure tone test

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由团队成员采用随机数字表的方法进行简单随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Simple randomization is performed by team members using the method of random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

对受试者设盲

Blinding:

blinding subjects

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-05-24 16:32:01